Using AI to make a big impact for emerging and mid-sized biopharma companies

With recent market changes catalysing a rapid shift to an omnichannel approach, life science organisations of every size are racing to adapt their commercial approach to be more relevant, coordinated and personalised to the needs of each HCP.

Artificial intelligence (AI) tools hold the key to delivering intelligent engagement at scale – especially for mid-sized organisations and smaller markets with lean commercial and data science teams.

Read the source article at pharmaphorum.com
2021-05-28 16:22:17